Kadmon (NYSE:KDMN) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Kadmon (NYSE:KDMNGet Rating) in a report issued on Wednesday. The brokerage set a “sell” rating on the stock.

Shares of NYSE:KDMN opened at $9.50 on Wednesday. The stock’s fifty day moving average is $9.50. Kadmon has a fifty-two week low of $3.19 and a fifty-two week high of $9.50.

Kadmon Company Profile (Get Rating)

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Recommended Stories

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.